 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
The Cost Effectiveness of Lowering Cholesterol in Individual Patients
16 May 2000 | Volume 132 Issue 10 | Page 769
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics". It is in the 16 May 2000 issue of Annals of Internal Medicine (volume 132, pages 769-779). The authors are L.A. Prosser, A.A. Stinnett, P.A. Goldman, L.W. Williams, M.G.M. Hunink, L. Goldman, and M.C. Weinstein.
What is the problem and what is known about it so far?
National guidelines recommend cholesterol-lowering treatment on the basis of an individual patient's cholesterol levels and risk factors for heart disease. However, using drugs to lower cholesterol levels is expensive. It is unclear for which types of patients this cost is worth the benefit. Statins are the major type of medicines used to lower cholesterol levels.
Why did the researchers do this particular study?
The researchers wanted to find out how the costs and benefits of cholesterol-lowering therapy vary with individual patient risk factors, including age, sex, smoking, blood pressure, and levels of "good" (high-density lipoprotein, or HDL) and "bad" (low-density lipoprotein, or LDL) cholesterol.
Who was studied?
The researchers used computers to simulate what would happen to a "virtual" group of 35- to 84-year-old patients who had high LDL cholesterol levels (at least 160 mg/dL, or 4.1 mmol/L).
How was the study done?
The authors divided the virtual patients into 240 separate groups according to various combinations of cholesterol level and other risk factors. They used information from actual patients to estimate what might happen when each group of patients was treated with diet alone, received statin drugs, or received no cholesterol-lowering treatment. They measured how much a particular treatment approach would cost for each additional quality-adjusted life-year (QALY) it saves. The QALYs take into account how well people are during those years.
What did the researchers find?
Compared with no treatment, the costs of diet alone seemed nearly always worth the benefit, except perhaps for women 35 to 44 years of age who had no risk factors. The costs of using statin drugs to treat patients who had already had a heart attack (secondary prevention) was always less than $50,000 per QALY saved, which compares favorably with the costs of many other accepted health interventions. The costs of lowering cholesterol levels with statin drugs in persons who had few risk factors and had not already had a heart attack (primary prevention) were, however, very high; they were greater than $100,000 per QALY in younger men and up to $1,400,000 per QALY in younger women.
What were the limitations of the study?
This study was a computer simulation. We cannot be sure what the results would be with actual patients. These estimates can be useful, however, because studies of this problem using actual patients are unlikely to be done soon, if ever. The findings may not apply to patients younger than 35 or older than 84 years of age and to cholesterol-lowering drugs other than statins.
What are the implications of the study?
For people who have already had a heart attack, the benefits associated with statin drugs appear to be worth the costs. However, among those who have not had a heart attack, the cost-effectiveness of statin drugs varies greatly depending on the risk factors present in each patient.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. J. Pletcher, L. Lazar, K. Bibbins-Domingo, A. Moran, N. Rodondi, P. Coxson, J. Lightwood, L. Williams, and L. Goldman Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering Ann Intern Med, February 17, 2009; 150(4): 243 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Diamond and S. Kaul Cost, Effectiveness, and Cost-Effectiveness Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 49 - 54. [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Russell Preventing Chronic Disease: An Important Investment, But Don't Count On Cost Savings Health Aff., January 1, 2009; 28(1): 42 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Steiner, W. D. Brown, and E. Liles An Assessment of the New Lipid Screening Guidelines Pediatrics, October 1, 2008; 122(4): 904 - 905. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Gill and Yingxia Chen Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records American Journal of Medical Quality, September 1, 2008; 23(5): 375 - 381. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Nexoe, P. A. Halvorsen, and I. S. Kristiansen Review Article: Critiques of the risk concept -- valid or not? Scand J Public Health, December 1, 2007; 35(6): 648 - 654. [Abstract] [PDF]
|
|
|
|
 |
|
 P. S. Chan, B. K. Nallamothu, H. S. Gurm, R. A. Hayward, and S. Vijan Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease Circulation, May 8, 2007; 115(18): 2398 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fidan, B. Unal, J. Critchley, and S. Capewell Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010 QJM, May 1, 2007; 100(5): 277 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rodondi, P. Yerly, A. Gabriel, W. F. Riesen, M. Burnier, F. Paccaud, and P. Bovet Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1107 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H Franco, E. W Steyerberg, A. Peeters, and L. Bonneux Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention. J Epidemiol Community Health, October 1, 2006; 60(10): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Chelmowski Cost-effectiveness of statins added to aspirin therapy. Ann Intern Med, August 1, 2006; 145(3): 233 - 233. [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone Cost-Effectiveness of Statins Added to Aspirin Therapy. Ann Intern Med, August 1, 2006; 145(3): 233 - 234. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dalziel, L. Segal, and M. de Lorgeril A Mediterranean Diet Is Cost-Effective in Patients with Previous Myocardial Infarction J. Nutr., July 1, 2006; 136(7): 1879 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zwanziger, W. J. Hall, A. W. Dick, H. Zhao, A. I. Mushlin, R. M. Hahn, H. Wang, M. L. Andrews, C. Mooney, H. Wang, et al. The Cost Effectiveness of Implantable Cardioverter-Defibrillators: Results From the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2310 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Cornuz, A Gilbert, C Pinget, P McDonald, K Slama, E Salto, and F Paccaud Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison Tob. Control, June 1, 2006; 15(3): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. T. Ayas, J. M. FitzGerald, J. A. Fleetham, D. P. White, M. Schulzer, C. F. Ryan, R. Ghaeli, G. W. Mercer, P. Cooper, M. C. Y. Tan, et al. Cost-effectiveness of Continuous Positive Airway Pressure Therapy for Moderate to Severe Obstructive Sleep Apnea/Hypopnea. Arch Intern Med, May 8, 2006; 166(9): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Hall Religious Attendance: More Cost-Effective Than Lipitor? J Am Board Fam Med, March 1, 2006; 19(2): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Clouse, J. Chen, H. M. Krumholz, M. E. Clouse, J. Chen, and H. M. Krumholz Noninvasive Screening for Coronary Artery Disease With Computed Tomography Is Useful Circulation, January 3, 2006; 113(1): 125 - 146. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Katon, M. Schoenbaum, M.-Y. Fan, C. M. Callahan, J. Williams Jr, E. Hunkeler, L. Harpole, X.-H. A. Zhou, C. Langston, J. Unutzer, et al. Cost-effectiveness of Improving Primary Care Treatment of Late-Life Depression Arch Gen Psychiatry, December 1, 2005; 62(12): 1313 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H Franco, A. Peeters, C. W N Looman, and L. Bonneux Cost effectiveness of statins in coronary heart disease J Epidemiol Community Health, November 1, 2005; 59(11): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Smith and R. L. Keeney Your Money or Your Life: A Prescriptive Model for Health, Safety, and Consumption Decisions Management Science, September 1, 2005; 51(9): 1309 - 1325. [Abstract] [PDF]
|
|
|
|
|
|
H.T. Ong The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient QJM, August 1, 2005; 98(8): 599 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Beinfeld, E. Wittenberg, and G. S. Gazelle Cost-effectiveness of Whole-Body CT Screening Radiology, February 1, 2005; 234(2): 415 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pletcher, J. A. Tice, M. Pignone, and W. S. Browner Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis Arch Intern Med, June 28, 2004; 164(12): 1285 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Aronow, G. M. Novaro, M. S. Lauer, D. M. Brennan, A. M. Lincoff, E. J. Topol, D. J. Kereiakes, and S. E. Nissen In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization: A Propensity Analysis Arch Intern Med, November 24, 2003; 163(21): 2576 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
B. R. Schackman, K. A. Freedberg, M. C. Weinstein, P. E. Sax, E. Losina, H. Zhang, and S. J. Goldie Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults Arch Intern Med, November 25, 2002; 162(21): 2478 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Krumholz, W. S. Weintraub, W. D. Bradford, P. A. Heidenreich, D. B. Mark, and A. D. Paltiel Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it? J. Am. Coll. Cardiol., August 21, 2002; 40(4): 603 - 615. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Mark and M. A. Hlatky Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II Circulation, July 30, 2002; 106(5): 626 - 630. [Full Text] [PDF]
|
|
|
|
|
|
L. Wartofsky Update in Endocrinology Ann Intern Med, October 16, 2001; 135(8_Part_1): 601 - 609. [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Federman, A. S. Adams, D. Ross-Degnan, S. B. Soumerai, and J. Z. Ayanian Supplemental Insurance and Use of Effective Cardiovascular Drugs Among Elderly Medicare Beneficiaries With Coronary Heart Disease JAMA, October 10, 2001; 286(14): 1732 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Greenland, S. C. Smith Jr, and S. M. Grundy Improving Coronary Heart Disease Risk Assessment in Asymptomatic People: Role of Traditional Risk Factors and Noninvasive Cardiovascular Tests Circulation, October 9, 2001; 104(15): 1863 - 1867. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Clark Jr Cost-Effectiveness Analyses Ann Intern Med, September 4, 2001; 135(5): 382 - 382. [Full Text] [PDF]
|
|
|
|
|
|
J. Beaird Using Cost-Effectiveness To Target Cholesterol Reduction Ann Intern Med, August 21, 2001; 135(4): 299 - 300. [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Hulley, D. Grady, and W. S Browner Statins: underused by those who would benefit BMJ, October 21, 2000; 321(7267): 971 - 972. [Full Text]
|
|
|
|
 |
|
 Cost-Effectiveness of Cholesterol Reduction Journal Watch Cardiology, August 4, 2000; 2000(804): 9 - 9. [Full Text]
|
|
|
|
 |
|
 Do All Populations Benefit from Statin Drugs? Journal Watch Women's Health, July 26, 2000; 2000(726): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Cost-Effectiveness of Cholesterol Lowering Varies Widely Journal Watch (General), June 16, 2000; 2000(616): 3 - 3. [Full Text]
|
|
|
|
|
|
A. M. Garber Using Cost-Effectiveness Analysis To Target Cholesterol Reduction Ann Intern Med, May 16, 2000; 132(10): 833 - 835. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Waldmann, R. Levy, and B. S. Coller Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy Hematology, January 1, 2000; 2000(1): 394 - 408. [Abstract] [Full Text] [PDF]
|
|
